<DOC>
	<DOCNO>NCT02253654</DOCNO>
	<brief_summary>The purpose study compare two different dose method epoetin alfa effectiveness maintain Hemoglobin level 10.0 11.0 g/dL . Study Hypothesis : An alternative dosing method United States package insert specify method increase percent time Hemoglobin within prespecified range 10.0 to11.0 g/dL .</brief_summary>
	<brief_title>If Alternate Dosing Superior Maintaining Hb Between 10.0 11.0 g/dL CKD Subjects HD v Current USPI</brief_title>
	<detailed_description>To evaluate alternative dose algorithm use epoetin alfa superior maintain hemoglobin ( Hb ) within10.0 to11.0 g/dL subject chronic kidney disease ( CKD ) receive hemodialysis ( HD ) compare dose consistent United States package insert ( USPI )</detailed_description>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Informed consent obtain prior initiation studyspecific activities/procedures Age 18 old Prescribed hemodialysis TIW ≥12 week prior randomization Prescribed IV administration epoetin alfa TIW ≥ 12 week prior randomization Prescribed ≥ 3000 Units/week ( ie , ≥ 1000 Units/administration ) &lt; 90,000 Units/week ( ie , &lt; 30,000 Units/administration ) epoetin alfa 4 week prior randomization Received ≥ 4 dos epoetin alfa 2 week prior randomization Hb concentration ≤ 11.0 g/dL , per recent local laboratory value obtain 2 week prior randomization Hb concentration ≤ 11.0 g/dL , screen visit , use Hb point care device provide Amgen Iron replete , define transferrin saturation ( TSAT ) ≥ 20 % ferritin ≥ 100 ng/mL , per recent local laboratory value obtain 4 week prior randomization Currently receive treatment another investigational device drug study , less 30 day since end treatment another investigational device drug study ( ) prior randomization Other investigational procedure participate study exclude Systemic hematologic disease ( eg , sickle cell anemia , myelodysplastic syndrome , hematologic malignancy ) Current prior malignancy within 5 year randomization , exception nonmelanoma skin cancer , cervical breast ductal carcinoma situ Treatment malignancy ( eg , radiation , chemotherapy , hormone therapy biologics ) within 5 year randomization , exception locally excise nonmelanoma skin cancer , cervical breast ductal carcinoma situ Subject currently pregnant plan become pregnant treatment 30 day end treatment Subject currently breast feed planning breast feed treatment 30 day end treatment Females reproductive potential willing use acceptable method effective contraception treatment least 30 day end treatment Currently receive IV antibiotic Currently receive systemic immunosuppressive therapy know cause anemia , include treatment active hepatitis ( eg , azathioprine , mycophenolate mofetil , ≥ 10 mg prednisone [ equivalent ] /day , interferon ) Known HIV positive Known neutralizing antierythropoietic protein antibody Known sensitivity epoetin alfa Subject likely available complete protocolrequired study visit procedure , and/or comply require study procedure ( eg , plan vacation away dialysis unit 2 week ) best subject investigator 's knowledge History evidence clinically significant disorder , condition disease ( exception outline ) , opinion investigator Amgen physician , consult , would pose risk subject safety interfere study evaluation , procedures completion Previously enter study Occurrence follow within 8 week prior randomization : seizure clinically relevant active bleeding ( eg , gastrointestinal bleed ) RBC transfusion hospitalization observational stay &gt; 24 hour Uncontrolled hypertension , per investigator within 4 week prior randomization Expected schedule solid organ transplant ( eg , kidney ) within 40 week randomization Expected schedule change dialysis modality ( eg , peritoneal dialysis , home hemodialysis ) within 40 week randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Anemia</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Red Blood Cell Transfusion</keyword>
</DOC>